Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

Biotech leaders call for free press

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Acknowledgements

This letter represents solely the individual and personal views of the authors and signatories, and not those of their employers, companies, universities or any other organization or agency.

Author information

Authors and Affiliations

Authors

Consortia

Corresponding authors

Correspondence to Steven Holtzman or John M Maraganore.

Ethics declarations

Competing interests

John Maraganore is CEO and board member of Alnylam Pharmaceuticals, and on the board of Agios Pharmaceuticals and the Biotechnology Innovation Organization. Steve Holtzman is president, CEO and board member of Decibel Therapeutics, and on the board of Molecular Partners. Ron Cohen is president and CEO of Acorda Therapeutics and a board member of VBL Therapeutics. Jeremy Levin is an officer at Ovid Therapeutics and on the board of Lundbeck A/S, Biocon Limited and ZappRX.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cohen, R., Holtzman, S., Levin, J. et al. Biotech leaders call for free press. Nat Biotechnol 36, 920–922 (2018). https://doi.org/10.1038/nbt.4271

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt.4271

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing